Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

• Status: RECRUITING
• Trial end date: 2026-12-01

Summary

This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma

• Phase: PHASE2

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: apatinib; Capecitabine; Cisplatin; Radiotherapy